Autologous cardiac micrografts as support therapy to coronary artery bypass surgery
medrxiv(2021)
摘要
Objectives Cardio-regenerative cell therapies offer additional biologic support to coronary artery bypass surgery (CABG) for treating the myocardium suffering from or damaged by ischemia. This phase 1, open-label study assessed the safety and feasibility of epicardial transplantation of atrial appendage micrografts (AAMs) in patients undergoing CABG surgery.
Methods Twelve consecutive patients destined for CABG surgery were included in the study. Six patients received AAMs during their operation and six patients were CABG-operated without AAMs treatment. Data from 30 elective CABG patients was collected for a conjunctive control group. The AAMs were processed during the operation from a biopsy collected from the right atrial appendage. They were delivered epicardially on the infarct scar site identified in preoperative CMR. The primary outcome measures at six-months follow-up were i) patient safety in terms of hemodynamic and cardiac function over time and ii) feasibility of therapy administration in a clinical setting. Secondary outcome measures were left ventricular wall thickness, change in myocardial scar tissue volume, changes in left ventricular ejection fraction, plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, NYHA class, number of days in hospital and changes in the quality of life.
Results Epicardial transplantation of AAMs was safe and feasible to be performed in conjunction with CABG surgery. CMR demonstrated an increase in viable cardiac tissue at the infarct site in patients receiving AAMs treatment.
Conclusion Transplantation of AAMs shows good clinical applicability as adjuvant therapy to cardiac surgery and can additionally serve as a delivery platform for cardiac gene therapies.
Trial Registration [ClinicalTrials.gov][1] identifier [NCT02672163][2]
### Competing Interest Statement
A.N and E.K. are stakeholders in EpiHeart Ltd developing medical devices for the operating room. H.S. is the developer of the 15D. Other authors declare no competing interests for this article.
### Clinical Trial
ClinicalTrials.gov identifier [NCT02672163][2]
### Funding Statement
This work was supported by A.H, M.K, A.V, and AN by Finnish Government Block Grants for Clinical Research (grant numbers TYH Y2016SK013, TYH2016211, TYH2015311, TYH2019266, Y1016SK017), E.K by Finnish Funding Agency for Technology and Innovation (grant number 40033/14) and A.N by Finnish Society of Angiology.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Surgical Ethics Committee of the Hospital District of Helsinki and Uusimaa (number 180/13/03/02/13).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data available on request due to privacy/ethical restrictions
* AB-BE
: Arterial astrup base excess
AAMs
: Autologous atrial appendage micrografts
ARB
: Angiotensin receptor blocker
BMI
: Body Mass Index
CABG
: Coronary artery bypass grafting
CCB
: Calcium channel blockers
CMR
: Cardiac magnetic resonance imaging
COPD
: Chronic Obstructive Pulmonary Disease
CVP
: Central venous pressure
ECG
: Electrocardiogram
ECM
: Extracellular matrix
EDV
: End diastolic volume
ESV
: End systolic volume
EF
: Ejection fraction
FWHM
: Full-width at half-maximum
GFR
: Glomerular filtration rate
Hb
: Hemoglobin
LA
: Left atrium
LBBB
: Left bundle branch block
LV
: Left ventricle
LVEDD
: Left ventricular end diastolic diameter
MAP
: Mean arterial pressure
MRA
: Mineralocorticoid receptor antagonists
NYHA
: New York Heart Association
NT-PRO-BNP
: N-terminal pro-B-type natriuretic peptid
PCI
: Percutaneous coronary intervention.
SD
: Standard deviation above the mean
SI
: signal intensity
SPO2
: Peripheral capillary oxygen saturation
STRM
: signal threshold versus reference mean
[1]: http://ClinicalTrials.gov
[2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02672163&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F12%2F2021.03.05.21252995.atom
更多查看译文
关键词
autologous cardiac micrografts,surgery
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要